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LIST OF ABBREVIATIONS (in the order of appearence) 
 
Ischemic heart disease     (IHD) 
Body mass index     (BMI) 
Arterial hypertension     (AHT) 
Thromboxane A2     (TXA2) 
Cyclo-oxygenase      (COX) 
Prostaglandin E       (PGE) 
Endothelium-derived prostacyclin    (PGI2) 
Messenger ribonucleic acid    (mRNA) 
Platelet endothelial cell adhesion molecule-1  (PECAM-1) 
Adenosine diphosphate     (ADP) 
Serine residue at position 529    (Ser529) 
Acetylsalicylic acid/aspirin    (ASA) 
Clopidogrel      (CLP) 
Coronary artery disease     (CAD) 
Acute myocardial infarction    (AMI) 
Transient ischemic attack     (TIA) 
Angiotensine converting enzyme    (ACE) 
Angiotensine II      (AT II) 
Calcium      (CA) 
Proton pump inhibitor     (PPI) 
Trimetazidine      (TMZ) 
Selective serotonin reuptake inhibitor   (SSRI) 
Red blood cell      (RBC) 
Cardiovascular disease     (CVD) 
Tissue plasminogen activator    (t-PA) 
C-reactive protein     (CRP) 
Platelet rich plasma     (PRP) 
Platelet poor plasma     (PPP) 
Standard deviation     (SD) 
Nonsteroidal anti-inflammatory drug   (NSAID) 
von Willebrand factor     (vWf) 
Soluble P-selectin     (sP-selectin) 
Cytochrome P 450     (CYP) 
Arachidonic acid      (AA) 
Percutaneous coronary intervention   (PCI) 
Vasodilator-stimulated phosphoprotein   (VASP) 
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1. INTRODUCTION 
 
1.1 Hemorheological parameters in atherothrombosis 
 
 Cardio- and cerebrovascular diseases and their complications are the leading cause of 
morbidity and mortality in the developed world. In the development of these diseases several 
factors are involved that interact with each other. While the role of “classic” risk factors (e.g., 
smoking, hypertension, hypercholesterolemia, diabetes mellitus, etc.) has been well known for 
a long time, the importance of hemorheologic parameters (hematocrit, fibrinogen, red blood 
cell deformability, red blood cell aggregation, plasma and whole blood viscosities) in the 
development of arteriosclerotic disorders has been accepted only in the last two decades. It is 
generally agreed that a rise in hemorheological factors leads to a state of hypoperfusion which 
results in impaired microcirculation (1-3). 
 Hemorheology is concerned with the flow properties of cellular and plasmatic 
components of blood. The resistance of blood to flow is known as blood viscosity. High blood 
viscosity slows down the blood flow and results in stasis and occlusion. Blood viscosity is 
determined by hematocrit, plasma viscosity, erythrocyte aggregation and cellular 
deformability. Since erythrocytes make up approximately 99% of the blood cells, erythrocyte 
deformability is an important parameter (4,5). 
Normal erythrocytes are significantly deformable. This property enables them to adapt 
well to flow conditions throughout the circulation. Due to the deformability of erythrocytes, 
blood viscosity is lower than the viscosity of a fluid containing non-deformable particles of 
the same size. When erythrocytes become less deformable, the viscosity of blood increases. 
The deformability of an erythrocyte is determined by three factors: viscoelasticity of its 
membrane which is controlled by a network of cytoskeletal proteins, biconcave-disk cell 
shape with a large ratio of surface area/cell volume, and intracellular viscosity which is 
mainly determined by hemoglobin concentration (5). 
The viscosity of plasma depends on its macromolecular content, the plasma proteins in 
particular. Among the plasma proteins, fibrinogen is the one that most affects plasma 
viscosity. Although fibrinogen constitutes a very small portion of the plasma proteins, its thin 
and long shape makes it an important determinant. Simple measurement of fibrinogen level 
thus may give an idea about plasma viscosity. However, protein–protein interactions also have 
important effects on plasma viscosity, especially during pathological conditions. 
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Determination of plasma viscosity by a viscometer not only reflects the effect of fibrinogen 
but that of protein–protein interactions as well (6) (see Figure1). 
   
 
 
 
Figure 1: The role of hemorheology in atherothrombosis. 
 
Several studies confirmed that hemorheological parameters are independent risk 
factors of ischemic heart disease (IHD) (7-10). While the role of “classic” risk factors has 
been noted a long time ago, recent clinical and epidemiological studies have provided 
compelling evidence that altered hemorheological parameters are also primary risk factors for 
the development and progression of cardio- and cerebrovascular diseases. Identifying elevated 
whole blood viscosity is of superior clinical importance since it has a predictive value for 
increased resistance to blood flow in the general circulation and for abnormal hemodynamics 
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in the microcirculation. Hemorheological parameters play a role in the development of 
ischemic areas causing insufficient circulation, local stasis, capillary clogging, thrombus 
formation, slow O2 transport and hypoxia. It promotes atherosclerotic plaque formation and 
shear stress damage at the endothelial wall leading to occlusive thrombus formation (7-10) 
(see Figure 1). „Classic” risk factors can also influence hemorheological parameters. A 
positive correlation between body mass index (BMI) and blood viscosity and its determinants 
has been demonstrated in several studies (11). Arterial hypertension (AHT) is in association 
with increased blood viscosity (12). Smoking increases in a reversible way plasma and whole 
blood viscosity, partly by increasing hematocrit and fibrinogen (9). 
Since 1993, results of a meta-analysis of six prospective epidemiological studies, 
including 14 988 persons for a total of 92 147 person-years investigated, showed that plasma 
fibrinogen is a powerful independent predictor of myocardial infarction and stroke (10). 
Afterwards, several prospective trials confirmed that increased whole blood viscosity, 
primarily dependent upon hematocrit value and fibrinogen concentration, is a major risk factor 
for ischemic heart disease and stroke (11-13). The relationships of these rheological variables 
to cardiovascular events are at least as strong as those of conventional risk factors (smoking 
habit, diastolic blood pressure, and low-density lipoprotein cholesterol) (13). 
At the same time, many investigations found that plasma fibrinogen concentration 
rises with advancing age (14-16). The Italian multicenter Study on Centenarians confirmed 
this result in a representative population group of very elderly. 
A few studies explored the relationship between rising age and whole blood viscosity. 
Nevertheless, some reports, based on the results of investigations carried out on very small 
population samples, tend to state that elderly healthy subjects display increased whole blood 
viscosity, but the results are still controversial (17,18). 
 
1.2 Platelet aggregation and inhibition in atherothrombosis 
 
Platelets are vital components of normal hemostasis and key participants in pathologic 
thrombosis by virtue of their capacity to adhere to injured blood vessels and to accumulate at 
sites of injury (19). Although platelet adhesion and activation should be viewed as a 
‘physiological’ response to the sudden fissuring or rupture of an atherosclerotic plaque, 
eventually contributing to its repair, uncontrolled progression of such a process through a 
series of self-sustaining amplification loops may lead to intraluminal thrombus formation, 
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vascular occlusion and transient ischemia or infarction (see Figure 2). Currently available 
antiplatelet drugs interfere with some steps in the activation process, including adhesion, 
release, and/or aggregation, and have a measurable impact on the risk of arterial thrombosis 
that cannot be dissociated from an increased risk of bleeding (20).  
 
 
 
Figure 2: Platelet adhesion, activation and aggregation. 
 
In discussing antiplatelet strategies, it is important to recognise that approximately 
1000 platelets are produced each day under physiological circumstances, a level of production 
that can increase up to tenfold at times of increased need (21). Platelets form by fragmentation 
of megakaryocyte cytoplasm and have a maximum circulating life span of about 10 days in 
man (21). Thus, platelets are anucleate blood cells that provide a circulating source of 
chemokines, cytokines and growth factors that are preformed and packaged in storage 
granules. Moreover, activated platelets can synthesize prostanoids [primarily, thromboxane 
(TX)A2] from arachidonic acid released from membrane phospholipids, through rapid 
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coordinated activation of phospholipase(s), cyclo-oxygenase (COX)-1 and TX-synthase3. 
Newly formed platelets also express the inducible isoforms of COX (COX-2) and 
prostaglandin E (PGE)-synthase, and this phenomenon is markedly amplified in association 
with accelerated platelet regeneration (22). Although activated platelets are not thought to 
synthesize proteins de novo, they can translate constitutive mRNAs into proteins, including 
interleukin-1 over several hours (23). Thus, platelets may have previously unrecognized roles 
in inflammation and vascular injury, and antiplatelet strategies may be expected to impact on 
platelet-derived protein signals for inflammatory and/or proliferative responses (23,24). 
Negative modulation of platelet adhesion and aggregation is exerted by a variety of 
mechanisms, including endothelium-derived prostacyclin (PGI2), nitric oxide, CD39/ecto-
ADPase and platelet endothelial cell adhesion molecule-1 (PECAM-1) (24-26). Some drugs 
may interfere with these regulatory pathways, as exemplified by the dose-dependent inhibition 
of PGI2 production by aspirin and other COX-inhibitors (19).  The apparent redundancy of 
mechanisms of endothelial thromboresistance is likely to limit the clinical consequences of 
PGI2 inhibition by COX-inhibitors. 
 Aspirin induces a long-lasting functional defect in platelets, which can be detectable 
clinically as a prolonged bleeding time. This appears to be primarily, if not exclusively, due to 
permanent inactivation by aspirin of a key enzyme in platelet arachidonate metabolism (see 
Figure 3). This enzyme, prostaglandin (PG) H-synthase, is responsible for the formation of 
PGH2, the precursor of TXA2. In human platelets, TXA2 provides a mechanism for 
amplifying the activation signal through its being synthesized and released in response to 
various platelet agonists  (e.g., collagen, adenosine diphosphate [ADP], plateletactivating 
factor, thrombin) and, in turn, inducing irreversible aggregation (27). Aspirin selectively 
acetylates the hydroxyl group of a single serine residue at position 529 (Ser529) within the 
polypeptide chain of platelet PGH-synthase. This enzyme exhibits two distinct catalytic 
activities: a bis-oxygenase (cyclo-oxygenase [COX]) involved in formation of PGG2, and a 
hydroperoxidase allowing a net two-electron reduction in the 15-hydroperoxyl group of 
PGG2, thus yielding PGH2. Through O-acetylation of Ser529 by aspirin, the cyclo-oxygenase 
activity is lost permanently, whereas the hydroperoxidase activity is not affected. An 
inducible form of PGH-synthase has been identified and termed PGH-synthase 2 or COX-2 
(28). Aspirin inhibits the cyclo-oxygenase activity of PGH-synthase 2, but at higher 
concentrations than those required to inhibit PGHsynthase 1 or COX-1 (i.e. the constitutive 
enzyme) (29).  
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Figure 3: The antiaggregatory mechanism of widely used antiplatelet agents. 
 
This may account, at least in part, for the different dose requirements of analgesic and 
anti-inflammatory versus antiplatelet effects of the drug. A very large database of randomized 
clinical trials now offers the most compelling evidence that prevention of myocardial 
infarction and ischemic stroke by aspirin is largely due to permanent inactivation of platelet 
COX-1 (19). These studies, which tested the efficacy and safety of the drug when given at 
daily doses ranging from as low as 30 mg to as high as 1500 mg, have established two 
important facts. First, the anti-thrombotic effect of aspirin is saturable at doses in the range of 
75 to 100 mg, as would be expected from human studies of platelet COX-1 inactivation (27). 
Second, despite a half-life of approximately 20 min in the human circulation, the anti-
thrombotic effect of aspirin is observed with dosing intervals of 24 to 48 hours, reflecting the 
permanent nature of platelet COX-1 inactivation and the duration of TXA2 suppression 
following oral dosing in man (27). Other mechanisms of action that have been suggested to 
contribute to the anti-thrombotic effect of aspirin, such as an anti-inflammatory effect of the 
drug, are simply incompatible with these unique properties. Although the search for the 
lowest effective dose of aspirin for platelet inhibition was largely driven by the explicit 
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concern of concomitant inhibition of vascular PGI2 production, it is still uncertain whether 
dosedependent suppression of the latter attenuates the anti-thrombotic effect of aspirin in 
clinical syndromes of vascular occlusion (27). The biochemical selectivity of low dose aspirin 
arises from both pharmacokinetic determinants, such as the acetylation of platelet COX-1 that 
occurs in portal blood (prior to first-pass metabolism), and pharmacodynamic determinants, 
such as the limited sensitivity of endothelial COX-2 to the drug. Aspirin is an effective anti-
thrombotic agent in a wide range of daily doses. Whether dose-dependent inhibition by aspirin 
of a mediator of thromboresistance, such as PGI2, may be responsible for a somewhat 
attenuated efficacy at high daily doses remains to be demonstrated convincingly (19,27,28). 
Aspirin's unique feature in inhibiting platelet COX-1 (i.e. its ability to inactivate the 
enzyme permanently through a short-lived active moiety) is ideally suited to its role as an 
antiplatelet drug, because they severely limit the extent and duration of extraplatelet effects of 
the drug, including the inhibition of PGI2. Moreover, the cumulative nature of platelet COX-1 
acetylation by repeated low doses of aspirin16 explains the clinical efficacy of doses as low as 
30 to 50 mg daily, the predictable high-grade inhibition of platelet TXA2 biosynthesis, and 
the persistence of the drug's effect. These features, in turn, may limit the consequences of less-
than-ideal compliance in a real world setting. Permanent inactivation of platelet COX-1 by 
aspirin may lead to the prevention of thrombosis as well as to excess bleeding. At least two 
distinct COX-1-dependent mechanisms contribute to the increased risk of upper GI bleeding 
associated with aspirin exposure: inhibition of TXA2-mediated platelet function and 
impairment of PGE2-mediated cytoprotection in the gastrointestinal (GI) mucosa (19,27). 
Whereas the former effect is dose independent, at least for daily doses > 30 mg, the latter 
effect is clearly dose-dependent. Inhibition of platelet function is largely responsible for the 2-
fold increase in the risk of upper GI bleeding associated with daily doses of aspirin in the 
range of 75 to 100 mg, in as much as a similar relative risk is associated with other antiplatelet 
agents that do not act on COX and therefore do not affect PGE2-mediated cytoprotection 
(29,30). Inhibition of COX-1-dependent cytoprotection amplifies risk of bleeding/ perforation 
by causing new mucosal lesions or aggravating existing ones, and is associated with a relative 
risk of four to six at the higher, analgesic or antiinflammatory doses of aspirin. Assessing the 
net effect of aspirin requires an estimation of the absolute risk of the individual patient for 
thrombotic or hemorrhagic complications. In individuals at very low risk for vascular 
occlusion (i.e. less than 1% per year), a very small absolute benefit may be offset by exposure 
of very large numbers of healthy subjects to undue serious bleeding complications. As the risk 
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of experiencing a major vascular event increases, so does the absolute benefit of antiplatelet 
prophylaxis with aspirin and, above a certain threshold, benefit clearly outweighs risk of 
bleeding (19,27). 
 Clopidogrel is structurally related the thienopyridines with platelet inhibitory 
properties. This drug selectively inhibits ADP-induced platelet aggregation, with no direct 
effects on the metabolism of arachidonic acid (19). Clopidogrel can also inhibit platelet 
aggregation induced by collagen and thrombin, but this inhibitory effect is abolished by 
increasing the agonist concentration and, therefore, likely reflect blockade of ADP-mediated 
amplification of the response to other agonists. Clopidogrel do not affect ADP-induced 
platelet aggregation when added in vitro up to 500 µM, thus suggesting that in vivo hepatic 
transformation to an active metabolite, or metabolites, is necessary for its antiplatelet effects. 
A short-lived, active metabolite of clopidogrel has been characterized (31). Recent evidence 
suggests that clopidogrel and, probably, ticlopidine induce irreversible alterations of the 
platelet ADP receptor P2Y12 mediating inhibition of stimulated adenylyl cyclase activity by 
ADP (32) (see Figure 3). Inhibition of platelet function by clopidogrel is associated with a 
selective reduction in ADP-binding sites, with no consistent change in the binding affinity. 
Permanent modification of an ADP receptor by thienopyridines is consistent with time-
dependent, cumulative inhibition of ADP-induced platelet aggregation on repeated daily 
dosing and with slow recovery of platelet function on drug withdrawal (19). 
After single oral doses of clopidogrel, ADP-induced platelet aggregation was inhibited 
in a dose-dependent fashion in healthy volunteers, with an apparent ceiling effect (i.e. 40% 
inhibition) at 400 mg. Inhibited platelet aggregation was detectable 2 hours after oral dosing 
of 400 mg, and it remained relatively stable up to 48 hours. With repeated daily dosing of 50 
to 100 mg in healthy volunteers, ADP-induced platelet aggregation was inhibited from the 
second day of treatment (25–30% inhibition) and reached a steady state (50–60% inhibition) 
after 4 to 7 days. Such maximal inhibition is comparable to that achieved with ticlopidine 
(500 mg daily). Ticlopidine, however, has shown a slower onset of antiplatelet effect 
compared with clopidogrel (33). 
The best available interpretation of these findings is that the active metabolite of 
clopidogrel has a pharmacodynamic pattern quite similar to that of aspirin in causing 
cumulative platelet inhibition on repeated daily low-dose administration (19,33). As with 
aspirin, platelet function returned to normal 7 days after the last dose. Both the cumulative 
nature of the inhibitory effects and the slow recovery rate of platelet function are consistent 
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with the active moieties of aspirin (i.e. acetylsalicylic acid) and clopidogrel (i.e. active 
metabolite) causing a permanent defect in a platelet protein that cannot be repaired during the 
24-h dosing interval and can be replaced only through platelet turnover (33). This also 
justifies the oncedaily regimen of both drugs despite their short half-life in the circulation. 
Bleeding times measured in the same multiple-dose study of clopidogrel described earlier 
showed a comparable prolongation (by 1.5–2.0-fold over controls) at 50 to 100 mg daily 
(19,33). 
Clopidogrel has undergone an unusual clinical development, with limited phase II 
studies and a single, large phase III trial (i.e. CAPRIE) to test its efficacy and safety at 75 mg 
daily compared with aspirin at 325 mg daily. Clopidogrel was slightly more effective than 
aspirin, and there was some suggestion from a marginally significant heterogeneity test that 
clopidogrel may be particularly effective at preventing vascular events in patients with 
symptomatic peripheral arterial disease. This interesting and, perhaps, unexpected finding 
suggests that the pathophysiologic importance of TXA2 and ADP varies in different clinical 
settings. In the CAPRIE trial, the frequency of severe rash was higher with clopidogrel than 
with aspirin (absolute excess approximately 1–2 per 1000), as was the frequency of diarrhoea, 
thus reproducing the characteristic side effects of ticlopidine. No excess neutropenia, 
however, was associated with clopidogrel, the frequency of this serious complication was 
extremely low (0.05 %) in this trial (34).  The CURE trial has demonstrated the efficacy and 
safety of adding clopidogrel (a loading dose of 300 mg, followed by 75 mg daily) to aspirin in 
the long-term management of patients with acute coronary syndromes without ST-segment 
elevation (35). Moreover, the combination of aspirin and clopidogrel has become standard 
treatment for 1 month after coronary stent implantation. The recently reported CREDO trial 
has demonstrated that following percutaneous coronary interventions, long-term (1-year) 
clopidogrel therapy significantly reduces the risk of adverse ischemic events (19,33-35). 
 Aspirin and clopidogrel have emerged as critical therapies in the treatment of 
cardiovascular diseases. Despite their efficacy, patients on these medications continue to 
suffer complications. Millions of patients are currently on low-dose antiplatelet therapy, but it 
is unknown how many of these patients are under-treated or on the wrong medication.  The 
term “aspirin resistance” or “clopidogrel resistance” has been used in a clinical and laboratory 
context. ‘Clinical aspirin resistance’ or ‘clinical clopidogrel resistance’ have been used to 
refer to the inability of these drugs to protect individuals from cardiovascular thrombotic 
events such as acute MI. Furthermore, the diagnosis of clinical resistance can only be made in 
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retrospect because an ischemic event must occur before a diagnosis of clinical resistance can 
be considered. ‘Laboratory aspirin resistance’ or ‘laboratory clopidogrel resistance’ refer to 
the lack of an anticipated effect of these antiplatelet drugs on a laboratory measure of its 
antiplatelet effect that is associated with a higher rate of future cardiovascular events (37-39). 
As the mechanisms of aspirin and clopidogrel resistance are becoming clearer, 
defining these clinical entities remains a challenge. The lack of a standard definition of 
resistance as well as the lack of a standard diagnostic modality have hampered the field in 
identifying and treating this clinical entity. Attempts have been made to develop a more 
meaningful definition with the goal of correlating laboratory tests with clinical outcomes, but 
there is no current definition which unifies the biochemical and clinical expression of failed 
treatment. Rates of aspirin resistance range from 5 to 45% of the population depending on the 
study and the method of determining therapeutic failure. Rather than attempting to 
characterize patients as simply resistant or sensitive to a medication, however, therapeutic 
resistance is more likely a continuous variable similar to blood pressure. By shifting the 
paradigm of diagnosis from a specific value to this notion of a continuous variable, the 
physiology of treatment failure may be better elucidated and thus better managed. In the 
meantime, a clear and consistent characterization of antiplatelet resistance is necessary (37-
39). 
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2. AIMS OF THE INVESTIGATIONS 
 
 
1. The aim of our first study was to examine the relationship of hemorheological parameters 
to the “classic” risk factor, advancing age.  
 
2. The aim of our second study was to compare some parameters of patients with effective 
platelet inhibition by aspirin (ASA) (risk profile, previous diseases, medication, and 
hemorheological parameters) to patients with ineffective ASA treatment. 
 
3. The aim of our third study was to compare some parameters of patients with effective 
platelet inhibition by clopidogrel (CLP) (risk profile, previous diseases, medication, 
hemorheological parameters, plasma von Willebrand factor and soluble P-selectin levels) to 
patients with ineffective clopidogrel treatment. 
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3. HEMORHEOLOGICAL PARAMETERS AND AGING 
 
Cardio- and cerebrovascular diseases and their complications are the leading cause of 
morbidity and mortality in the developed world. While the role of “classic” risk factors (e.g. 
smoking, hypertension, hypercholesterolemia, diabetes, etc.) has been well known for a long 
time, the importance of hemorheologic parameters in the development of coronary artery 
disease (CAD) has been accepted only in the last two decades. „Classic” risk factors can also 
influence hemorheological parameters. A positive correlation between body mass index 
(BMI) and blood viscosity and its determinants has been demonstrated in several studies. 
Arterial hypertension is in association with increased blood viscosity. Smoking increases in a 
reversible way plasma and whole blood viscosity, partly by increasing hematocrit and 
fibrinogen. The relationships of these rheological variables to cardiovascular events are at 
least as strong as those of conventional risk factors (smoking habit, diastolic blood pressure, 
and low-density lipoprotein cholesterol). 
The aim of our present study was to determine the association between 
hemorheological parameters (hematocrit, fibrinogen, red blood cell aggregation, plasma and 
whole blood viscosity) and increasing age, because a relatively few number of studies 
examined the association between these parameters and increasing age, and their results are 
controversial. 
 
3.1 Patients and methods 
3.1.1 Patients 
 Between January 1999 and May 2004 the blood samples of 6236 cardio- and 
cerebrovascular patients (3774 males, mean age 59.8+/-13.2 years and 2462 females, mean age 
60.9+/-12.8 years) were examined in our laboratory. Both sexes were divided into three 
categories: A. young patients: <45 years. B, middle-aged patients: 45-65 years and C, old 
patients: >65 years. To evaluate the possible effect of risk profile, 623 patients from the study 
population with matching parameters were divided into the three age groups as mentioned 
before. They had the same prevalence of risk factors  including body mass index, smoking habits, 
diabetes mellitus, dyslipidemia, hypertension), previous diseases (pulmonary embolism, deep 
vein thrombosis, ischemic heart disease (IHD), acute myocardial infarction (AMI), stenosis of 
the carotid artery, transient ischemic attack (TIA),  stroke and peripheral arterial disease and took 
the same medication beta-blockers, alpha blockers, angiotensine converting enzyme (ACE) 
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inhibitors, angiotensine II (AT II) receptor antagonists, calcium (CA) channel blockers, 
nitrates, statins, fibrates, diuretics, H2 receptor blockers, proton pump inhibitors (PPI), 
acetylsalicylic acid (ASA), clopidogrel (CLP), trimetazidine (TMZ), vinpocetine and 
pentoxyphylline (see Table 1). 
 
3.1.2. Methods 
 
3.1.2.1 Hemorheological measurements 
Blood samples were taken from the cubital vein; routine blood chemistry and hemorheological 
parameters - hematocrit, plasma fibrinogen level, plasma and whole blood viscosity, red blood 
cell (RBC) aggregation and deformability - were determined. 
 Hematocrit: 
Venous blood collected into lithium-heparin coated Vacutainer tubes was used to determine 
hematocrit. Hematocrit was measured by centrifuging hematocrit capillaries (80 µl, containing 
heparin) at 12000 rpm for five minutes in microhematocrit centrifuge (Hemofuge, Heraeus Instr., 
Germany). Measurements were performed at room temperature (22 ± 1 ºC). 
Plasma fibrinogen: 
4.5 ml blood sample was drawn into a Vacutainer tube containing sodium citrate (0.129 M, 
1:10 dilution) and plasma fibrinogen concentration was determined by using Clauss’s method 
(40). 
 Plasma and whole blood viscosity: 
Venous blood samples were collected into lithium-heparin coated Vacutainer tubes for 
viscosity measurements. Plasma was prepared by centrifuging samples at 1500 g for ten 
minutes. Plasma and whole blood viscosities were determined in Hevimet 40 capillary 
viscosimeter (Hemorex Ltd., Hungary). 1.0-1.0 ml of plasma or whole blood was injected into 
the capillary tube of the device. In this viscosimeter the flow of the fluid is detected 
optoelectronically along the capillary tube and a flow curve is drawn. Shear rate and shear stress  
are calculated from this curve, viscosity values are determined as a function of these parameters 
according to Casson's principle (41). For the presentation of our results, apparent whole blood 
viscosity values calculated at 90 s-1 shear rate are given. Measurements were carried out at 37.0 
± 0.5 ºC within 2 hours after venepuncture. 
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Table 1: Baseline characteristics in the selected population 
 
 RBC aggregation: 
 RBC aggregation measurements were carried out from venous blood samples collected into 
lithium-heparin coated Vacutainer tubes. RBC aggregation was measured in Myrenne 
aggregometer (MA-1 Aggregometer, Myrenne GmbH, Germany) applying the light 
transmission method. In this study the aggregometer was used in low shear (M1) mode. In this 
 young 
patients 
 n = 119 
middle-aged patients 
 n = 226 
old patients 
n = 278 
Mean age (mean ± SEM) 32.4 ± 0.15 
 
54.1 ± 0.1 
 
72.4 ± 0.12 
 
BMI (kg/m2) (mean ± SEM) 26.95 ± 0.08 27.11 ± 0.06 27.32 ± 0.05 
Smoking (%) 34 31 32 
Diabetes mellitus (%) 46 49 45 
Hyperlipidemia (%) 44 41 42 
Hypertension (%) 60 62 65 
Pulmonary embolism (%) 5  6  4  
Deep vein thrombosis (%) 9  11  8  
IHD (%) 32  31  34  
AMI (%) 15  17  19  
Stenosis of the carotid artery (%) 5  6  8  
TIA (%) 2  3  2  
Stroke (%) 12  14  13  
Peripheral arterial disease (%) 13  11  14  
β-blockers (%) 42  40  41  
α-blockers (%) 12 14  10 
ACE-inhibitors (%) 45 48 49 
AT-II-receptor blockers (%) 4  3  3  
Ca-channel blockers (%) 30 28  31 
Nitrates (%) 12 13 13  
Statins (%) 26 28 30 
Fibrates (%) 2  3  3  
Diuretics (%) 12 14 15  
H2-receptor blockers (%) 18  19  18  
PPI (%) 22  23  25  
ASA (%) 55  56  56  
CLP (%) 12  13  11  
TMZ (%) 18  19  19  
Vinpocetine (%) 19  17  16  
Pentoxyphilline (%) 8  11  12  
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mode blood sample (30 µl) is first sheared at 600 s-1 to disperse all pre-existing aggregates, 
then shear rate decreases rapidly to low shear (3 s-1). The extent of aggregation is 
characterized by the aggregation index (AI), calculated from the surface area below the light 
intensity curve in a 10 s measurement period (42,43). Measurements were performed at room 
temperature (22 ± 1 ºC) within 2 hours after venepuncture. 
3.1.2.2. Statistical analysis 
Data were evaluated as means ± S.E.M. (standard error of mean) by Student’s t test 
and chi square test. 
 
3.2 Results 
3.2.1 Whole population 
3.2.1.1 Hematocrit 
Hematocrit level slightly, but significantly increased with advancing age (p < 0.01) in 
the whole population as well as in males and females. Analyzing the data of the different age 
subgroups we found that hematocrit increased with age in the young and middle-aged males (p < 
0.05), while it decreased significantly in the old patients (p < 0.01). On the other hand, in females a 
significant positive correlation could only be found in young patients (p < 0.01). Young patients 
had significantly lower hematocrit levels (p < 0.01) compared to the other two age groups. There 
was no difference between middle-aged and old patients in either sexes. 
3.2.1.2 Plasma fibrinogen 
Plasma fibrinogen significantly increased with age (p < 0.01) in the studied population 
and also in both genders (p < 0.05). In the different age subgroups positive correlation could be 
found in old males and middle-aged females (p < 0.01). Young patients had significantly lower 
plasma fibrinogen levels (p < 0.01) compared to the other two age groups. 
3.2.1.3. Red blood cell aggregation 
There was a significant correlation between red blood cell aggregation and advancing 
age in both males and females (p < 0.05). Analyzing the subgroups, we found a significant 
positive correlation in young males and significantly decreasing values in the case of old males 
(p < 0.05). Young patients had significantly lower red blood cell aggregation level compared to 
the other groups (p < 0.001). 
3.2.1.4. Plasma viscosity 
Plasma viscosity significantly increased with age when both sexes were considered 
together (p < 0.01). This finding remained significant in males, but not in females (p < 0.01).  
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Table 2: Correlation coefficient (2-tailed) and its significancy in the whole population 
(*correlation is significant at the 0.05 level (2-tailed), ** is significant at the 0.01 level ) 
 
 
Table 3: Mean values ± SEM in the whole population  (' p < 0.05, * p<0.01, ** p< 0.001) 
 whole 
population 
n = 6236 
males 
 
n = 3774 
females 
 
n = 2462 
young 
males 
n = 309 
middle-
aged 
males 
n = 1687
old  
males 
 
n = 1778
young 
females 
n = 212 
middle-aged 
females 
n = 1098 
old 
females 
 
n = 1152 
mean age (mean ± SEM) 60.3 ± 
0.03 
 
59.8 ± 
0.03 
 
60.9 ± 
0.05 
 
36.1 ± 0.1 
 
56.8 ± 
0.07 
 
70.8 ± 
0.06 
 
35.1 ± 0.08 
 
58.5 ± 0.03 
 
70.9 ± 
0.03 
hematocrit r=0.049** 
 
r=0.069** 
 
r=0.066** 
 
r=0.147** 
 
r=0.074*
 
r=-
0.11** 
 
r=0.255** 
 
r=-0.015 
 
r=-0.064 
 
fibrinogen r=0.108** 
 
r=0.105** 
 
r=0.077* 
 
r=0.068 
 
r=0.053 
 
r=0.99**
 
r=-0.011 
 
r=0.105** 
 
r=0.036 
 
red blood cell 
aggregation index 
r=0.098** 
 
r=0.102** 
 
r=0.09* 
 
r=0.398** 
 
r=-0.05 
 
r=-
0.085* 
 
r=0.05 
 
r=0.002 
 
r=-0.093 
 
plasma viscosity r=0.148** 
 
r=0.18** 
 
r=0.085 
 
r=0.159** 
 
r=0.032 
 
r=0.031 
 
r=-0.011 
 
r=0.039 
 
r=0.034 
 
whole blood viscosity r=0.083** 
 
r=0.124** 
 
r=0.047 
 
r=0.117 
 
r=0.042 
 
r=-
0.101** 
 
r=0.05 
 
r=0.001 
 
r=-0.045 
 
 males females young 
males 
middle-
aged 
males 
old  males young 
females 
middle-aged 
females 
old females 
hematocrit (%) 44.79 ± 
0.4  
41.88 ± 
0.3 
43.6 ± 0.3 
*  
45.1 ± 0.2 44.9 ± 0.3 40.22 ± 0.4 
* 
42.3 ± 0.4 41.8 ± 0.3 
fibrinogen (g/l) 3.392 ± 
0.06 
3.429 ± 
0.07 
3.28 ± 
0.08  
3.38 ± 
0.08 
3.44 ± 
0.07 
3.07 ± 0.09 3.43 ±0.11 3.48 ± 0.1 
red blood cell 
aggregation index 
25.21 ± 
0.32 
25.41 ± 
0.33 
22.69 ± 
0.3 ** 
25.89 ± 
0.34 
25.36 ± 
0.30 
23.06 ± 0.4 
** 
25.68 ± 0.36 25.60 ± 0.27 
plasma viscosity (mPas) 1.28 ± 
0.01  
1.30 ± 
0.01  
1.22 ± 
0.01 
 ' 
1.29 ± 
0.01 
1.29 ± 
0.01  
1.27 ± 0.01  
' 
1.31 ± 0.01 1.30 ±0.01 
whole blood viscosity 
(mPas) 
4.79 ± 
0.04  
4.42 ± 
0.06 
4.46 ± 
0.04 
* 
4.88 ± 
0.04  
4.83 ± 
0.05  
4.27 ± 0.04  
* 
4.47 ± 0.06 4.41 ± 0.07 
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Examining the age groups we could find a significant correlation only in young men (p 
< 0.01). Lower plasma viscosity values could be found in young patients compared to the other 
groups (p < 0.05). 
3.2.1.4. Whole blood viscosity 
Whole blood viscosity significantly increased with age in the whole population (p < 
0.01), but analyzing the sex groups we could find a significant negative correlation only in old 
males (p < 0.01). Young patients had lower whole blood viscosity values than middle-aged and 
old patients (p< 0.01) (see Tables 3 and 4). 
 
3.2.2 Selected population 
 
All the measured parameters did not correlate with increasing age neither in the 
selected population nor in the subgroups. No significant difference could be found in the 
mean values of the different subgroups (see Tables 4 and 5). 
 
 Whole 
population 
n = 623 
males  
 
n = 309 
females  
 
n = 226 
young  
males  
n = 75 
middle-aged 
males  
n = 146 
old males  
 
n = 176 
young 
females 
n = 44 
middle-aged 
females  
n = 80 
old females  
 
n = 102 
hematocrit r = 0.063  
 
r = 0.024  
 
 
r = 0.047  
 
r = 0.098  
 
 
r = 0.042  
 
 
r = - 0.051  
 
r = 0.078 
 
 
r = 0.01  
 
 
r = - 0.015  
 
 
fibrinogen r = 0.14 
 
r = 0.124  
 
r = 0.147  
 
r = 0.155 
 
r = 0.07  
 
r = - 0.02 
 
 
r = 0.138 
 
 
r = 0.098  
 
r = 0.017  
 
 
red blood cell 
aggregation index 
r = 0.089 
 
r = 0.104  
 
r = 0.067  
 
r = 0.11 
 
r = 0.047  
 
r = - 0.072 
 
 
r = 0.10 
 
 
r = 0.038  
 
 
r = - 0.03  
 
 
plasma viscosity r = 0.067 
 
r = 0.074  
 
r = 0.047  
 
 
r = 0.052 r = 0.037  
 
 
r = 0.022 
 
 
r = 0.079 
 
 
r = 0.018  
 
 
r =  0.035  
 
 
whole blood 
viscosity 
r = 0.056 
 
r = 0.064  
 
 
r = 0.029  
 
r = 0.060 
 
r = 0.017  
 
 
r = - 0.062 
 
r = 0.092 
 
 
r = 0.035  
 
 
r =  - 0.028  
 
 
 
 
Table 4: Correlation coefficient and its significancy in the homogenous population 
(*correlation is significant at the 0.05 level (2-tailed), ** is significant at the 0.01 level ) 
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Table 5: Mean values ± SEM in the homogenous population  
(' p < 0.05, * p<0.01, ** p< 0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 males 
 
  
 
females 
 
 
 
young males 
 
 
middle-aged 
males 
 
old males 
 
 
 
young 
females 
 
middle-aged 
females 
 
old females 
 
 
 
hematocrit (%) 44.2 ± 0.5  41.6 ± 0.3 43.8 ± 0.3  44.3 ± 0.2  44.5 ± 0.3  41.01 ± 0.4 41.8 ± 0.4 41.9 ± 0.3 
fibrinogen (g/l) 3.35 ± 0.04 3.36 ± 0.07 3.33 ± 0.09  3.37 ± 0.07 3.44 ± 0.06 3.29 ± 0.1 3.32 ±0.1 3.38 ± 0.1 
red blood cell 
aggregation index 
24.5 ± 0.3 24.8 ± 0.31 24.1 ± 0.25  25.3 ± 0.35 25.3 ± 0.30 24.5 ± 0.31  24.9± 0.3 25.1 ± 0.2 
plasma viscosity 
(mPas) 
1.27 ± 0.01  1.28 ± 0.01  1.25 ± 0.01   1.29 ± 0.01 1.29 ± 0.01  1.28 ± 0.01   1.31 ± 0.01 1.30 ±0.01 
whole blood 
viscosity (mPas) 
4.68 ± 0.04  4.46 ± 0.06 4.58 ± 0.04  4.68 ± 0.04  4.73 ± 0.05  4.47 ± 0.04  4.47 ± 0.06 4.46 ± 0.07 
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DISCUSSION 
 
Since 1993, results of a meta-analysis of six prospective epidemiological studies, 
including 14 988 persons for a total of 92 147 person-years investigated, showed that plasma 
fibrinogen is a powerful independent predictor of myocardial infarction and stroke (10). 
Afterwards, several prospective trials confirmed that increased whole blood viscosity, 
primarily dependent upon hematocrit value and fibrinogen concentration, is a major risk factor 
for ischemic heart disease and stroke (11-13). The relationships of these rheological variables 
to cardiovascular events are at least as strong as those of conventional risk factors (smoking 
habit, diastolic blood pressure, and low-density lipoprotein cholesterol) (13). 
On the other hand, the role of hemoheological parameters still remains unclear. A 
number of clinical studies have demonstrated significant positive correlation between the 
severity of arterial hypertension (AHT) and whole blood viscosity. Red blood cell aggregation 
has also been associated with AHT especially in the severe form of the disease. The main 
possible cause of increased red blood cell aggregation is fibrinogen which can be found in a 
significantly higher concentration in patients with AHT than in healthy controls. On the other 
hand, blood pressure reduction with angiotensin-converting-enzyme inhibitors, calcium-
channel-blocking agents, beta or alpha-receptor blocking drugs leads to a significant 
improvement of blood rheology. It can be presumed that abnormal hemorheology and AHT 
are not directly linked but they share the same inductive genetic and/or environmental factors 
like obesity, chronic mental stress, physical inactivity and cigarette smoking. Regarding this 
hypothesis, the appropriate question is not whether hemorheological factors are causes or 
results of AHT but what their common origins are. Further studies are needed to clarify this 
hypothetical link between hemorheology and AHT (44). 
Despite the statistically significant association between hematocrit and coronary heart 
disease in the general population, the risk ratio is only slightly elevated above 1·0 and its 
relevance remains uncertain. Hematocrit levels are correlated with a number of standard 
vascular risk factors and adjustment for the measured values of these factors in some studies 
reduces the strength of the associations between hematocrit and coronary heart disease. 
Hence, adjustment for the longterm usual values of those factors (and other possible 
confounders) should reduce the risk ratio still further towards 1·0. It is also possible that the 
available evidence on hematocrit and coronary heart disease has been exaggerated somewhat 
by publication bias. Assays for hematocrit are widely available, so other relevant studies of 
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hematocrit and incident coronary heart disease may well exist (e.g., in trials of vascular 
disease prevention) that have not yet been reported. Indeed, separate results for coronary heart 
disease were not reported in a few long-term prospective studies of hematocrit and all-cause 
mortality, but any bias owing to the absence of these published studies is not likely to be 
substantial since they include less than 5% of the deaths in the available studies (45). 
A recent meta-analysis used data from the Edinburgh Artery Study, a population 
cohort study started in 1987 that comprised 1592 men and women aged 55 to 74 years. 
Subjects were followed for a mean of 17 years, and 416 of them suffered at least 1 
cardiovascular event. In analyses adjusted for cardiovascular risk factors and history of 
cardiovascular disease (CVD): C-reactive protein (CRP), interleukin-6, fibrinogen, fibrin D-
dimer, tissue plasminogen activator (t-PA), leukocyte elastase, and lipoprotein(a) (all p<0.01), 
as well as von Willebrand factor and plasma viscosity (both p<0.05), had significant hazard 
ratios for incident CVD. Further adjustment for a measure of subclinical atherosclerosis (ankle 
brachial index) had little impact on these associations. The hazard ratios (95% CI) for incident 
CVD between top and bottom tertiles in the latter analysis were 1.78 (1.30 to 2.45) for C-
reactive protein, 1.85 (1.33 to 2.58) for interleukin-6, and 1.76 (1.35 to 2.31) for fibrinogen 
(46). 
We examined the possible connection between increasing age and hemorheological 
parameters in 6234 cardio- and cerebrovascular patients first in the whole study population 
and later in the different subgroups. We found a very weak but statistically significant positive 
correlation between increasing age and hemorheological parameters in the whole population, 
but not in all subgroups. In the case of old males whole blood viscosity and its main 
determinants were negatively correlated with advancing age. These results suggest that these 
positive correlations are probably just statistically, but not clinically significant. In the second 
part of our study, in the selected population we did not find any significant correlation, not 
even in the subgroups. Our results suggest that these parameters are mostly independent of 
aging, increased values are not associated with older age but the more frequently occurring 
diseases. 
„Classic” risk factors can also influence hemorheological parameters. A positive 
correlation between body mass index (BMI) and blood viscosity and its determinants has been 
demonstrated in several studies (11). Arterial hypertension is in association with increased 
blood viscosity (12). Smoking increases in a reversible way plasma and whole blood 
viscosity, partly by increasing hematocrit and fibrinogen (9). Many drugs have potential 
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effects on hemorheological parameters (47,48). Relatively few study examined the 
associations between hemorheological parameters and increasing age. They reported a not 
very pronounced increase and these reports depended on the populations studied and were 
controversial (49-53). To evaluate the effect of risk profile, previous diseases and medication 
623 patients were selected from the examined group with the same parameters.   
In the homogenous population we did not find any significant correlation neither in the 
whole population nor in the subgroups. It is very similar to the findings of Coppola et al. (18) 
but they found age-related dicrease of hematocrit level in the case of old men, but they 
examined apparently healthy people who were free from clinically detectable illnesses and 
their biochemical routine parameters were normal. Our study and a recent study did confirm 
their findings except for the age-related decrease in hematocrit levels. A recent population 
based study led to the same result (54).  
  In our knowledge our study is the first which examined the correlation between 
hemorheological parameters to advancing age in homogenous vascular diseased patient 
population. The summary of our study is that these parameters are independent of aging, 
increased values are not associated with older age but the more frequently occurring diseases.  
Finally our study has some limitations. Our database did not contain the laboratory 
results of our patients. Plasma fibrinogen is also a low grade inflammation marker and is 
strongly associated with white blood cell count and CRP. Plasma lipids have great influence 
on plasma viscosity.  Further examinations are needed to study their influence on rheological 
and inflammatory parameters to advancing age in a multivariate analysis. 
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4. THE POTENTIAL BACKGROUND(S) OF ASPIRIN RESISTANCE 
 
There is no debate that long term aspirin use attenuates the risks of myocardial 
infarction, stroke, and vascular related deaths in patients with cardiovascular disease, but a 
significant number of patients prescribed aspirin as antithrombotic therapy have major adverse 
vascular related events each year. Consequently other antiplatelet agents in addition to aspirin 
have been prescribed for certain patients (37,39). 
The major controversy about aspirin therapy is why particular patients do not benefit 
from such therapy and how they might be identified. It has been suggested that some patients 
require a higher dose of aspirin than is normally recommended to achieve the expected 
antiplatelet effect - for example, inhibition of platelet function or inhibition of platelet 
thromboxane A2 synthesis. It is unclear whether these patients simply receive too low aspirin 
dose, are not compliant, have differing abilities to absorb aspirin, or have an underlying 
genetic disposition that renders aspirin ineffective. Such patients have been labelled aspirin 
“resistant” - that is, their platelets are not affected in the same way or are affected differently 
from the platelets of those who seem to benefit from aspirin therapy (aspirin “sensitive” 
patients with no subsequent adverse cardiovascular event). Little consistency exists about 
which measure should be used to identify patients who seem to be resistant to aspirin. Also, 
few studies have assessed the effect of aspirin resistance on clinically important outcomes 
(37,39). 
In the following experiments we examined the potential factors of aspirin resistance 
(ASA). 
 
4.1 Patients and methods 
4.1.1 Patients 
 Between March 2004 and April 2005, 99 consecutive chronic cardio- and 
cerebrovascular patients took part in our study. These patients were commenced on standard 
antiplatelet therapy with aspirin 100–325 mg/day. Patients were excluded from the study if 
they were taking any other antiplatelet or anticoagulant medications, had a history of other 
nonvascular diseases (e.g. hematological, endocrinological disorders or had recently 
experienced an acute vascular event (AMI, stroke or peripherial embolisation 3 months prior 
to the study). 
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4.1.2 Methods 
4.1.2.1 Platelet aggregation 
 Epinephrine-, ADP- and collagen-stimulated aggregation of platelets was analyzed. 
450 µl platelet rich plasma (PRP) was measured against 450 µl platelet poor plasma (PPP) to 
determine spontaneous platelet aggregation. 50 µl of ADP (5 and 10 µM), epinephrine (10 
µM) or collagen (2 µg/ml) was added to PRP so as to measure stimulated platelet aggregation. 
Platelet aggregation was measured using a Carat TX4 optical platelet aggregometer (Carat 
Diagnostics Ltd., Hungary). Platelet aggregation index has a “normal range” (mean ± 2 SD) to 
each stimulants in 68 untreated healthy persons (30 males, 38 females, mean age 38 ± 6 
years). If a platelet aggregation inhibitor drug is effective, it decreases the aggregation index 
induced by the appropriate agonists (55,56). ADP stimulation is used to estimate the effect of 
thienopyridines (ticlopidine and clopidogrel). In our study antiplatelet medication was 
considered to be effective if the aggregation index to the appropriate agonists (collagen 2 
µg/ml and epinephrine 10 µM) were lower than the range of untreated persons (both < 60 %) 
(56). 
4.1.2.2. Hemorheological measurements 
 Blood samples were taken from the cubital vein; routine blood chemistry and 
hemorheological parameters - hematocrit, plasma fibrinogen level, plasma and whole blood 
viscosity, RBC aggregation and deformability - were determined. Details can be seen under 
3.1.2 section on page 15-17. 
4.1.2.3. Risk profile and previous diseases 
 Risk profile and investigated previous diseases included body mass index (BMI), 
smoking habits, diabetes, hypertension, dyslipidemia, deep vein thrombosis, pulmonary 
embolism, ischemic heart disease (IHD), acute myocardial infarction (AMI), carotid stenosis, 
transient ischemic attack (TIA), stroke, and peripheral arterial disease. Exclusion criteria 
included previous acute myocardial infarction or stroke < 3 months, or documented IHD or 
cerebrovascular disease lasting < 1 year previous to our investigation, and any other than 
vascular disorders. Hypertension was diagnosed in the case of elevated blood pressure values 
(>140/90 mm Hg measured twice in a resting position) and in subjects with normal blood 
pressure (<140/90 mm Hg) but on antihypertensive therapy. Dyslipidemia was defined 
according to the following criteria: serum total cholesterol level >200 mg/dL, serum high 
density lipoprotein cholesterol level <40 mg/dL, or serum triglyceride level >195 mg/dL. The 
term “current smoker” was applied if the patient smoked at least 10 cigarettes a day or 
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consumed an equivalent daily dose of tobacco. Obesity was defined as a body mass index 
(BMI) >30 kg/m2. Diabetes mellitus was defined as fasting glucose > 130 mg/dL or patients 
with normal fasting blood glucose level but on antidiabetic medication. 
 
 
 
Table 6: Baseline characteristics of the study groups 
 ineffective inhibition 
of platelet aggregation  
(n = 132) 
effective inhibition of 
platelet aggregation  
(n = 467) 
p value 
Mean age (yrs) 62 ± 0.7 64 ± 0.7 n.s. 
Female/male ratio 0,48 0,52 n.s. 
Mean dosage (mg/daily) 123 ± 0,2 127 ± 0,3 n.s. 
Hypertension (%) 62 80 p < 0.05 
Dyslipidaemia (%) 45 49 n.s 
Deep vein thrombosis (%) 9 11 n.s 
Pulmonary embolism (%) 5 6 n.s 
IHD (%) 51 49 n.s 
AMI (%) 25 27 n.s 
Stenosis of the carotid artery (%) 11 12 n.s 
TIA (%) 11 8 n.s 
Stroke (%) 27 25 n.s 
Peripheral arterial disease (%) 13 11 n.s 
β-blockers (%) 55 75 p < 0.05 
α-blockers (%) 12 14 n.s 
ACE-inhibitors (%) 52 70 p < 0.05 
ATII -receptor  blockers (%) 3 4 n.s 
Ca-channel blockers (%) 33 28 n.s 
Statins (%) 52 38 p < 0.05 
Fibrates (%) 4 3 n.s 
Diuretics (%) 22 24 n.s 
Nitrates (%) 25 23 n.s 
H2-receptor blockers (%) 22 24 n.s 
PPI (%) 24 27 n.s 
TMZ (%) 33 29 n.s 
Benzodiazepines (%) 18 18 n.s 
SSRIs (%) 11 13 n.s 
Phosphodiesterase inhibitors (%) 18 20 n.s 
NSAIDs (%) 15 17 n.s 
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4.1.2.4. History of medication 
 History of medication was related to beta-blockers, alfa-blockers, angiotensine 
converting enzyme (ACE) inhibitors, angiotensine (AT) II receptor blockers, calcium (Ca) 
channel blockers, statins, fibrates, diuretics, nitrates, H2 receptor blockers, proton pump 
inhibitors (PPIs), trimetazidine, benzodiazepines, selective serotonine reuptake inhibitors 
(SSRIs), phosphodiesterase inhibitors (vinpocetine, pentoxyphilline), and nonsteroidal anti-
inflammatory drugs (NSAIDs). Exclusion criteria included clopidogrel/dipyridamole use or 
anticoagulation with warfarin. 
4.1.2.5. Statistical analysis: 
Data were evaluated as means ± SD (standard deviation) by Student’s t-test and the chi 
squire test. Logistic regression analysis was used to determine the significance of the different 
parameters as independent risk factors in the development of clopidogrel resistance. The 
analysis was performed with appropriate adjustments for differences in risk factors and 
medication usage. For all odds ratios, an exact CI of 95% was constructed in our study. 
Logistic regression analyses were performed using the statistical package of SPSS 11.0 
(SPSS, Chicago, IL, USA).  
 
4.2 Results 
 
4.2.1 Risk profile and previous diseases 
 The prevalence of hypertension was higher in the group of patients with effective 
inhibition (80 % vs. 62 %, p < 0.05). There was not any other difference in risk profile and 
previous diseases between the two groups. On the other hand, after the setup of logistic 
regression analysis between risk profiles and ASA resistance, hypertension did not seem to be 
an independent predictor 
4.2.2 History of medication 
 In the case of effective platelet aggregation beta-blockers (75 % vs. 55 %, p < 0.05) 
and ACE inhibitors (70 % vs. 50 %, p < 0.05), while in the group of ineffective platelet 
aggregation statins were taken more frequently (52 % vs. 38 %, p < 0.05) (see Table 6). After 
the setup of logistic regression analysis between medications and ASA resistance, only statins 
remained independent factors of ASA resistance (OR 5.92; 95% CI 1.83 to 16.9; p < 0.001). 
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4.2.3 Hemorheological variables 
 Patients with effective ASA inhibition had significantly lower plasma fibrinogen level 
(3,8 g/l vs. 3.3 g/l, p < 0.05) and red blood cell aggregation values (28.2 vs. 24.3, p < 0.01) 
(see Table 7). 
 
 
 Ineffective inhibition Effective inhibition p value 
hematocrit (%) 41 ± 0.2 42 ± 0.2 n.s 
fibrinogen (g/l) 3,8 ± 0.1 3,3 ± 0.1 p < 0.05 
red blood cell aggregation 28,2 ± 0.3 24,3 ± 0.2 p < 0.01 
plasma viscosity (mPas) 1,31 ± 0.03 1,3 ± 0.03 n.s 
whole blood viscosity at 90 1/s 
shear rate (mPas) 
4,62 ± 0.13 4,58 ± 0.11 n.s 
 
Table 7: Hemorheological parameters between the study groups. 
 (values are represented as mean value ± SEM) . 
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DISCUSSION 
 
 The term of ASA resistance has been used to describe a number of different 
phenomena, including the inability of ASA to accompanish the followings: 1. to protect 
individuals from thrombotic complications, 2. to cause a prolongation of bleeding time, 3. to 
reduce TXA2 production, or 4. to produce an anticipated effect on one or more in vitro tests of 
platelet function (57). Approximately one in eight high-risk patients will experience a 
recurrent atherothrombotic vascular event in the subsequent two years despite taking ASA, 
while it also fails to prevent 81 % of recurrent serious vascular episodes among high-risk 
patients. Resistance to this drug is the only one explanation as to why may not be absolutely 
effective in preventing recurrent vascular events. Other possible reasons include an incorrect 
diagnosis or noncompliance with the prescribed dosage of medication (58). There are other 
parameters which play an important role of ASA resistance. 
 Although several studies examined a set of different factors in ASA resistance by in 
vitro test of platelet inhibition, in our knowledge this was the first study which analysed the 
possible role of risk factors, previous diseases medication and hemorheological parameters 
together. 
Poor compliance may be the most important factor of ASA resistance. The higher 
prevalence of hypertension in the case of effective platelet inhibition may refer this, and it can 
explain the difference in the prevalence of ACE-inhibitors and beta-blockers. These patients 
can be tightly controlled by their general practitioners and it can cause better drug-taking 
compliance. A recent review showed the hazards of discontinuing aspirin. They concluded 
non-compliance or withdrawal of aspirin treatment has ominous prognostic implication in 
subjects with or at moderate-to-high risk for CAD. Aspirin discontinuation in such patients 
should be advocated only when bleeding risk clearly overwhelms that of atherothrombotic 
events (59). 
On the other hand, a recent study showed the potential platelet inhibitory effect of 
beta-blockers on collagen- and epinephrine-induced platelet aggregation (41), thus an additive 
effect of these drugs may be involved in the effective antiplatelet therapy. Other publications 
showed that the benefits of ASA and ACE inhibitors may be attenuated when both agents are 
used together, although other studies showed no effect of ACE-inhibitors on platelet 
aggregation (60-62). 
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Statins are widely used in cardiovascular diseases and their favourable effects were 
proven by many large-population studies, and they may partially be independent from plasma 
cholesterol levels, combining lipid-lowering with positive effects on hemorheological 
conditions and endothelial function (63,64). Statins are also reported to decrease platelet 
aggregation (65). Recent publications showed the inhibitory effect of statins (especially 
atorvastatin) on clopidogrel biovability (66,67), but other studies did not confirm this (68,69). 
Our results suggest that statins may interfere with ASA. 
Aspirin, dipyridamole, cilostazol, thienopyridines and glycoprotein IIb/IIIa inhibitors 
represent the classical examples of the established antiplatelet agents commonly used for the 
secondary prevention in patients after vascular events. Obviously, the era of expanding 
antiplatelet regimens and indications may require new agents as the substitutes, or additions to 
the available strategies. However, recent results of the majority of antiplatelet trials strongly 
suggest borderline advantages in clinical outcomes, and higher associated bleeding risks with 
the novel antiplatelet agents or/and regimens. Moreover, unexpected failures, such as lack of 
efficacy of clopidogrel and aspirin combination for ischemic stroke prevention (MATCH), or 
use of the same antiplatelet regimen for the primary vascular prevention (CHARISMA) raise 
legitimate concerns that the concept ‘the more the better’ may not be valid. Broad use of 
statins, angiotensin receptor blockers and selective serotonin reuptake inhibitors may be in 
part responsible for the lack of impressive results with the antiplatelet therapy because each of 
these drug classes per se inhibits platelets (70). Our results  showed the possible role of other 
agents on platelet aggregation and aspirin resistance.  
Several studies confirmed that hemorheological parameters are independent risk 
factors of IHD (45). They play a role in the development of ischemic areas causing 
insufficient circulation, local stasis, capillary clogging, thrombus formation, slow O2 transport 
and cause hypoxia. This is the first study which showed impaired hemorheological parameters 
as potential background of ASA resistance. When plasma fibrinogen level increases red blood 
cells adhere and release ADP, which is a potential agonist of platelet aggregation. On the 
other hand, the aggregated red blood cells migrate in the center of blood flow displacing other 
cells (platelets) in small vessels, so they can easily contact to the endothelium (46). In the case 
of effective platelet inhibition we found significantly lower plasma fibrinogen levels 
compared to the other group.This may be caused by the higher rate of ACE inhibitors, because 
their favourable effect on hemorheological parameters (especially fibrinogen and plasma 
viscosity) was shown in a recent study (63). Furthermore, platelets from aspirin-resistant 
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patients appeared to be more sensitive and activable by ADP. This hypersensitivity could 
provide a possible explanation for the so-called aspirin resistance, and this could justify 
therapeutic improvement with alternative antiplatelet agents (71).  
A recent meta-analysis showed that patients who are “resistant” to aspirin are at 
greater risk of clinically important adverse cardiovascular events, regardless of the assay used 
to measure aspirin resistance. Not only did aspirin resistance have an effect on clinical 
outcomes but this risk was not ameliorated by currently used adjunct antiplatelet therapies. 
Patients who were classified as aspirin resistant were at about a fourfold increased risk of non-
fatal and fatal cardiovascular, cerebrovascular, or vascular events while taking aspirin than 
their aspirin sensitive counterparts. This risk can be generalised to a wide variety of patient 
populations with cardiovascular or cerebrovascular diseases (72). Prospective randomized 
studies are warranted to elucidate the optimal aspirin dosage for preventing ischemic 
complications of atherothrombotic diseases. 
So, aspirin resistance seemed to be associated with worsening clinical outcome. Our 
study showed the role of hemorheological parameters in aspirin resistance. We also found 
antiplatelet effets beyond traditional antiplatelet agents, which may affect the efficacy of 
aspirin therapy. 
Finally, our study has some limitations. The baseline aggregation values of our 
patients were unknown because at the moment of the examination they already had 
antiplatelet medication. Their laboratory results were also not measured, which may influence 
the hemorheological parameters and they may play an important role in the mechanism(s) of 
resistance.  
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5. THE POTENTIAL BACKGROUND(S) OF CLOPIDOGREL RESISTANCE 
 
 Platelets have a central role in the development of arterial thrombosis and subsequent 
cardiovascular events. An appreciation of this has made antiplatelet therapy the cornerstone of 
cardiovascular disease management. Resistance to clopidogrel both in vitro and in vivo has 
also been described (38). Up to 5-11% of clopidogrel-treated patients were found to be non-
responders, while 9-26% were semi-responders (37,38), but the possible mechanisms are still 
unclear.  
 
5.1 Patients and methods 
 
5.1.1 Patients 
 157 chronic cardio- and cerebrovascular patients taking 75 mg clopidogrel daily (not 
combined with aspirin) as antiplatelet agent were involved in our study (83 males, mean age 
61 ±11 yrs, 74 females, 63 ±13 yrs). 
5.1.2 Methods 
5.1.2.1 Platelet aggregation 
5.1.2.2. Hemorheological measurements 
5.1.2.3 Risk profile and previous diseases 
5.1.2.4 History of medications 
 All these parameters can be seen under 4.1.2 on page 25-27. 
5.1.2.5 Measurement of von Willebrand factor 
 A quantitative direct enzyme immunoassay (Shield Diagnostics Ltd., U.K.) was used 
for the detection of von Willebrand factor (vWf) activity in human citrated plasma. The wells 
of the microtitre strips are coated with a preparation of purified monoclonal antibody which 
recognizes a functional epitope on the vWf antigen. During first incubation the specific 
antigen in diluted plasma will bind to the antibody coating. The wells are then washed to 
remove unbounded plasma components. A conjugate of horseradish-peroxidase-labelled 
mouse anti-human monoclonal anti-vWf conjugate binds to surface-bound antigen in the 
second incubation. After a further washing step, specifically-bound antibody is traced by the 
addition of substrate solution. Addition of stop solution terminates the reaction. The amount 
of conjugate bound is measured in absorbance units. The activity of vWf in unknown sample 
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can be estimated by interpolation from a dose-response curve prepared from calibrator set 
according to the 4th International Standard (73). 
 
 
Table 8: Clinical characteristics of the study groups 
 
 
 ineffective inhibition of platelet 
aggregation (n = 35) 
effective inhibition of platelet 
aggregation (n = 122) 
p value 
Mean age (yrs) 62 ± 5 62 ± 6 n.s 
Male/female ratio 0.56 0.58 n.s 
Mean daily dosage (mg) 75 75 n.s 
BMI (kg/m2) 28.8 ± 0.7 26.1 ± 0.6 0.04 
Smoking (%) 27 24 n.s 
Diabetes mellitus (%) 36 39 n.s 
Hypertension (%) 62 65 n.s 
Dyslipidemia (%) 51 49 n.s 
IHD (%) 52 51 n.s 
AMI (%) 22 21 n.s 
Stenosis of the carotid artery (%) 10 11 n.s 
TIA (%) 7 7 n.s 
Stroke (%) 20 21 n.s 
Peripheral arterial disease (%) 8 9 n.s 
Deep vein thrombosis (%) 6 7 n.s 
Pulmonary embolism (%) 2 3 n.s 
β-blockers (%) 56 55 n.s 
α-blockers (%) 5 6 n.s 
ACE-inhibitors (%) 51 50 n.s 
ATII receptor blockers (%) 3 4 n.s 
Ca-channel blockers (%)  28 31 n.s 
Statins (%) 52 48 n.s 
Fibrates (%) 3 3 n.s 
Nitrates (%) 25 24 n.s 
Diuretics (%) 15 17 n.s 
H2 receptor inhibitors (%) 3 4 n.s 
PPI (%) 10 9 n.s 
Trimetazidine (%) 63 69 n.s 
Benzodiazepines (%) 25 10 0.03 
SSRIs (%) 28 12 0.04 
Phosphodiesterase inhibitors (%) 12 16 n.s 
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5.1.2.6 Measurement of sP-selectin factor 
 Determination of the level of sP-selectin was performed by using a sandwich ELISA 
procedure according to manufacturer’s instructions (Bender MedSystems, Austria) using the 
previously mentioned steps. sP-selectin was determined from platelet poor plasma prepared as 
described above. 
5.1.2.6. Statistical analysis 
 All these parameters can be seen under 4.1.2 on page 26. 
 
5.2 Results 
 
5.2.1 Platelet aggregation 
 Among 157 chronic cardio- and cerebrovascular patients involved in our study we 
found ineffective platelet aggregation in 35 patients (22 %). There was no significant 
difference in the mean age, the male/female ratio, the dosage of CLP and the duration of 
therapy between the two groups. 
5.2.2 Risk profile and previous diseases  
 Patients with effective inhibition had lower BMI (28,8 kg/m2 vs. 26,1 kg/m2, p < 
0.05). There was not any other difference in the prevalence of different risk factors and 
previous diseases between the two groups (Table 2). After the setup of logistic regression 
analysis between risk profiles and CLP resistance, BMI remained to be independent factor of 
CLP resistance (OR 2.62; 95% CI: 1.71 to 3.6; p < 0.01) (see Table 8). 
5.2.3 History of medication 
 In the case of ineffective platelet inhibition, benzodiazepines (25 % vs. 10 %, p < 
0.05) and selective serotonin reuptake inhibitors (28 % vs. 12 %, p < 0.05) were taken more 
frequently (Table 1). After the setup of logistic regression analysis between risk profiles and 
CLP resistance, they remained to be independent factors of CLP resistance (benzodiazepines: 
OR 5.83; 95% CI: 2.53 to 7.1; p < 0.05 and SSRIs: OR 5.22; 95% CI: 2.46 to 6.83; p < 0.05) 
(see Table 8).  
5.2.4 Hemorheological variables and adhesive molecules 
 There were no significant differences in the hemorheological parameters and in the 
plasma level of adhesive molecules between the two groups (see Table 9). 
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 ineffective inhibition effective inhibition p value 
hematocrit (%) 44 ± 0.2 43 ± 0.3 n.s 
fibrinogen (g/l) 3.7 ± 0..4 3.6 ± 0.04 n.s 
red blood cell aggregation (%) 29.2 ± 0..22 28.3 ± 0.21 n.s 
plasma viscosity (mPas) 1.31 ± 0.01 1.30 ± 0.01 n.s 
whole blood viscosity at 90 1/s 
shear rate (mPas) 
4.68 ± 0.03 4.62 ± 0.03 n.s 
 
Table 9. Hemorheological parameters in the study groups 
(values are represented as mean value ± SEM) 
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DISCUSSION 
 
 Platelet aggregation is a key event in arterial thrombosis. It is also involved in the 
initiation and development of atherosclerotic lesions, through platelet adhesion to 
dysfunctional endothelium and release of growth factors and cytokines (19). Adenosine 
diphosphate (ADP) belongs to the key mediators of platelet stimulation and mediates its effect 
through two 7 transmembrane receptors, P2Y1 and P2Y12 (32). P2Y12 plays a particularly 
important role in platelet aggregation, since its coupling to a GI protein is responsible both for 
stabilizing platelet aggregates and for amplifying aggregation induced by ADP and other 
agonists (66). The importance of the ADP receptor P2Y12 is emphasized by the fact that 
patients with cardiovascular diseases derive a greater benefit when platelet aggregation is 
blocked by thienopyridines than when platelet function is inhibited by aspirin (33). 
Clopidogrel-induced platelet inhibition is patient-specific (37,38). The concept of clopidogrel 
resistance has emerged in the medical literature to reflect the failure to inhibit platelet function 
in vitro, although its existence and definition remain to be established. It has been proposed 
that the term resistance encompasses patients for whom clopidogrel does not achieve its 
pharmacological effect, and failure of therapy reflects patients who have recurrent events on 
therapy (37). The prevalence of clopidogrel nonresponse in patients is evaluated between 4% 
and 30% 24 h after administration (37,38). The reported rates vary between studies because of 
the technique used to measure the extent of platelet aggregation and the presence of factors 
contributing to greater baseline platelet reactivity. Furthermore, the definition of 
nonresponders is not standardized. We defined clopidogrel resistance as an inadequate 
decrease of the aggregation index induced by the appropriate agonists compared to healthy 
volunteers. We found that higher BMI is an independent factor of clopidogrel resistance, 
which is in concordance with the results of Angiolillo et al. (74,75). High dose of clopidogrel 
(600 mg loading dose) was shown to be more effective compared with 300 mg (76). Our 
results suggest that long term treatment should be weight-adjusted. There were no other 
differences in cardiovascular risk profile or previous disease history between the two groups, 
although smoking might play an important role of clopidogrel metabolism by the way of P 
450 1A2 (38). Many drugs have an increasing effect of platelet function (77), thus they may 
be associated with platelet inhibition. Certain statins were reported to may decrease the 
efficacy of clopidogrel treatment by the way of CYP3A4 (37,38). In our study statins did not 
interfere with the efficacy of clopidogrel, but SSRIs and benzodiazepines did. Recent studies 
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showed that benzodiazepines, especially alprazolam, triazolam and midazolam are 
metabolised and eliminated by CYP3As. It is also shown that certain SSRIs, as fluvoxamine 
are potent inhibitors of CYP1A2 and nefazodone is a potent inhibitor of CYP3A4, which 
isoenzymes play an important role in clopidogrel metabolism (78-80). CYP3A4 activity plays 
a role in clopidogrel resistance and metabolic interactions on this isoenzyme may decrease the 
metabolism and antiplatelet effect of clopidogrel (81). On the other hand, diazepam and 
clonazepam in a concentration-dependent manner inhibited thrombin, ADP or AA-stimulated 
platelet aggregation and the thrombin-induced increase in free intracellular Ca2+ (82). Thus 
receptorial interactions may also play a role in this phenomenon. The severity of 
atherosclerosis may be associated with resistance to antiplatelet therapy in patients treated 
with aspirin (37). The level of hemorheological parameters, von Willebrand factor and P-
selectin were shown to be correlated with the progression of atherosclerosis (82). Our findings 
suggest that clopidogrel resistance may not be associated with the progression of 
atherosclerosis. 
 A recent systematic review on prevalence and clinical consequences of laboratory-
defined clopidogrel nonresponsiveness among patients undergoing PCI indicates that in 
approximately 1 in 5 of them, clopidogrel nonresponsiveness can be found and that this 
condition appears to be related to worsened clinical outcomes. Our results indicate that use of 
a 600-mg clopidogrel loading dose in patients undergoing PCI may result in a more rapid and 
stronger antiplatelet effect, which needs to be confirmed in large prospective studies. Future 
studies are also warranted to examine which method and time of determining clopidogrel 
nonresponsiveness could be used in clinical practice to identify patients at the highest risk. 
Furthermore, there is a clear need for future studies addressing alternative strategies for these 
high risk patients (83). 
 A recent study suggested that adjusting clopidogrel loading dose according to platelet 
reactivity measured by VASP index is safe and may significantly improve clinical outcome 
after PCI in patients with clopidogrel resistance. Moreover, the very high sensitivity of the 
VASP index at a cutoff value of 50% may be considered of clinical interest in avoiding 
subacute stent thrombosis and may justify routine monitoring for clopidogrel resistance in 
high-risk population subsets (84). 
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In summary, our study is among the first studies which examined the potential 
background(s) of clopidogrel resistance. Clopidogrel resistance is a clinical entity with serious 
outcome. Monitoring and adjusting the antiplatelet therapy may be associated with decreased 
recurrent vascular events. We showed that BMI is associated with low response to clopidogrel 
and psychotropic agents (benzodiazepines and SSRIS) but not statins may inhibit the 
metabolism of clopidogrel possibly by the way of CYP3A4 and CYP1A2. Finally, our study 
had some limitations. The baseline aggregation values of our patients were unknown because 
at the moment of the examination they already were on antiplatelet medication. Their blood 
chemistry was also not measured, and these parameters might influence the hemorheological 
parameters (especially hyperlipidemia) and they may play a role in the mechanism of 
resistance. Finally, we did not examine the patients directly, their data (BMI, high blood 
pressure, etc.) were extracted from hospital case notes. 
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6. SUMMARY 
 
Although we have the data of several large trials, the role of hemorheological 
parameters and their possible relation to age is still under-represented in circulation research 
and in the clinical practice. „Classic” risk factors can also influence hemorheological 
parameters. A positive correlation between BMI and blood viscosity and its determinants has 
been demonstrated in several studies. Arterial hypertension is in association with increased 
blood viscosity. Smoking increases in a reversible way plasma and whole blood viscosity, 
partly by increasing hematocrit and fibrinogen. Many drugs have potential effect on 
hemorheological parameters. Relatively few study examined the associations between 
hemorheological parameters and increasing age. They reported a not very pronounced 
increase and these reports depended on the populations studied and are controversial. To 
evaluate the effect of risk profile, previous diseases and medication, 623 patients were 
selected from the examined group with the same parameters. Our results suggest, that in a 
homogenous population, hemorheological parameters are independent of aging, thereby 
altered hemorheological parameters are much more associated with different diseases and the 
severity of atherosclerosis, than with aging alone.  
 Our study investigating the efficacy of routine antiplatelet medication confirmed the 
existence of both aspirin and thienopyridine non-responder individuals in the general 
population. Many different ways to perform aggregometry have been published. All tests have 
in common that their widespread clinical use is substantially limited due to complex 
preanalytic factors, reduced specificity and reproducibility. The results of these tests may 
become more comparable after the standardization of the different methods.  
 There is no debate that long term antiplatelet use attenuates the risks of myocardial 
infarction, stroke, and vascular related deaths in patients with cardiovascular diseases, but a 
significant number of patients prescribed antiplatelet as antithrombotic therapy have major 
adverse vascular related events each year. The major controversy about antiplatelet therapy is 
why particular patients do not benefit from such therapy and how they might be identified. It 
has been suggested that some patients require a higher dose of antiplatelet than is normally 
recommended to achieve the expected antiplatelet effect - for example, inhibition of platelet 
function or inhibition of platelet thromboxane A2 synthesis. It is unclear whether these 
patients simply receive too low antiplatelet dose, are not compliant, have differing abilities to 
absorb antiplatelet, or have an underlying genetic disposition that renders antiplatelet 
  40
ineffective. Such patients have been labelled antiplatelet “resistant” - that is, their platelets are 
not affected in the same way or are affected differently from the platelets of those who seem 
to benefit from antiplatelet therapy (antiplatelet “sensitive” patients with no subsequent 
adverse cardiovascular event). Little consistency exists about which measure should be used 
to identify patients who seem resistant to antiplatelet. Also, few studies have assessed the 
effect of antiplatelet resistance on clinically important outcomes. 
 A recent systematic review on prevalence and clinical consequences of laboratory-
defined clopidogrel nonresponsiveness among patients undergoing PCI indicates that in 
approximately 1 in 5 of them, clopidogrel nonresponsiveness can be found and that this 
condition appears to be related to worsened clinical outcomes. Our results indicate that use of 
a 600-mg clopidogrel loading dose in patients undergoing PCI may result in a more rapid and 
stronger antiplatelet effect, which needs to be confirmed in large prospective studies. Future 
studies are also warranted to examine which method and time of determining clopidogrel 
nonresponsiveness could be used in clinical practice to identify patients at the highest risk. 
Furthermore, there is a clear need for future studies addressing alternative strategies for these 
high risk patients. 
 A recent meta-analysis showed that patients who are “resistant” to aspirin are at 
greater risk of clinically important adverse cardiovascular events, regardless of the assay used 
to measure aspirin resistance. Not only did aspirin resistance have an effect on clinical 
outcome but this risk was not ameliorated by currently used adjunct antiplatelet therapies. 
Patients who were classified as aspirin resistant were at about a fourfold increased risk of non-
fatal and fatal cardiovascular, cerebrovascular, or vascular events while taking aspirin than 
their aspirin sensitive counterparts. This risk can be generalised to a wide variety of patient 
populations with cardiovascular or cerebrovascular disease. Prospective randomized studies 
are warranted to elucidate the optimal aspirin dosage for preventing ischemic complications of 
atherothrombotic disease. 
The mechanisms underlying antiplatelet resistance can be multifactorial. Impaired 
hemorheological parameters (especially plasma fibrinogen) seemed to be associated only with 
aspirin, but not with clopidogrel resistance. When plasma fibrinogen level increases red blood 
cells adhere and release ADP, which is a potential agonist of platelet aggregation. On the 
other hand, the aggregated red blood cells migrate in the center of blood flow displacing other 
cells (platelets) in small vessels, so they can easily contact to the endothelium, releasing ADP, 
which is a strong agonist of platelet activation. 
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In the case of effective platelet inhibition we found significantly lower plasma 
fibrinogen levels compared to the other group.  
Increasing BMI was associated with lower response to clopidogrel therapy. We found 
that higher BMI is an independent factor of clopidogrel resistance, which is in concordance 
with the results of previous studies. Our results suggest that long term treatment should be 
weight-adjusted.  
Statins remained an independent predictor of aspirin resistance and benzodiazepines 
and SSRIs remained an independent predictor of clopidogrel resistance even after adjustment 
for risk factors and medication use. The COX-1 enzyme dependent antiplatelet effect of 
statins has been previously showed. They may interfere with the COX-1 inhibitory effect of 
aspirin. Recent studies showed that benzodiazepines, especially alprazolam, triazolam and 
midazolam are metabolised and eliminated by CYP3As. It is also shown that certain SSRIs, as 
fluvoxamine are potent inhibitors of CYP1A2 and nefazodone is a potent inhibitor of 
CYP3A4, which isoenzymes play an important role in clopidogrel metabolism. CYP3A4 
activity plays a role in clopidogrel resistance and metabolic interactions on this isoenzyme 
may decrease the metabolism and antiplatelet effect of clopidogrel.  Our result showed the 
potential antiplatelet effect of different (not antiplatelet) agents, which may affect the efficacy 
of routine antiplatelet therapy. 
 Finally, despite of recent clinical trials and meta-analysises, the definition of 
antiplatelet resistance is still unclear. The role of other parameters (especially the role of drug 
interactions) is poorly studied. Large, population based, randomized studies are needed to 
clarify the previous results.  
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